Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease

SUVr measurement in lesions by 18F-FDG PET images

1. For AD and PD outcome assessment uses 18F-FDG-PET images for qualitative and quantitative follow-up. The SUVr improvement of 20% or more from baseline is considered a good outcome.An increase in SUVr of less than 20% from the baseline period is considered steady state.Decreased SUVr from baseline was considered a poor outcome 2. For EP and MBT outcome assessment uses 18F-FDG-PET images for qualitative and quantitative follow-up. A reduction in SUVr of more than 70% from baseline period measurements was considered a good outcome. A 50-70% reduction in SUVr from baseline period measurements was considered a stable outcome.A decrease of less than 50% or an increase in SUVr from baseline period measurements was considered a poor outcome.

MMSE score for AD

Outcome evaluation of PET/MR diagnosed AD patients with MMSE and MOCA scores after treatment

UPDRS evaluation for PD

Using UPDRS for Post-Treatment Assessment in PET/MR Diagnosed PD: UPDRS scores post PET/MR-diagnosed PD guide prognosis categorization: good, stable, poor outcomes. Ranges vary slightly but generally are: * Good Prognosis: Significant symptom improvement, UPDRS scores 0-30. * Stable Prognosis: Minimal changes, UPDRS scores 31-60. * Poor Prognosis: Limited improvement or worsening, UPDRS scores 61+. UPDRS scores assess treatment efficacy, inform care decisions after PET/MR-based PD diagnosis.

Engle level for EP

Patients with PET/MR diagnosis and localized epileptic foci were evaluated for efficacy by applying engle grading at 3, 6, and 12 months of treatment Disease-specific clinical score follow-up indicators:Engle classification score at 6 months, 1 year, and 2 years post-treatment follow-up, Engle Ia for good prognosis, Engle Ib-IV for poor prognosis

RANO score for MBT

Patient outcomes based on RANO scores were evaluated at 3, 6, and 12 months post-treatment for those with malignant brain tumors confirmed by PET/MR diagnosis and postoperative pathology. After treatment, RANO criteria guide follow-ups for brain tumor patients. These criteria standardize response evaluation, aiding treatment assessment and management decisions. Responses fall into categories: * Complete Response (CR): No measurable tumor remains on scans; tumor disappearance indicates successful treatment response. * Partial Response (PR): Tumor size reduces; significant decrease in burden suggests positive treatment impact. * Stable Disease (SD): Minimal tumor size change; fluctuations not meeting progression or response criteria. * Progressive Disease (PD): Tumor increases or new lesions appear; growth or spread despite treatment. Responses are assessed using MRI and clinical factors, considering tumor size and patient condition.